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Practical Modalities for Prevention of Fungal 
Infections in Cancer Patients
B.E. De Pauw
Invasive fungal infections have become a major obstacle to the treatment of patients 
with malignancies. Candida spp. and Aspergillus spp. now rank among the ten most 
prominent pathogens in these patients. Currently, there are no adequate means of de­
tecting these infections at an early stage, and optimal hygiene and elimination of well- 
known sources of infection remain the most important preventive measures. Due to the 
lack of reliable, randomized studies, the role of antifungal drugs in the prevention of in­
vasive fungal infections is difficult to judge. The clinical impact of the older oral antifun­
gal agents is questionable, and compliance with therapeutic regimens of these drugs 
is often limited. In prospective studies in bone marrow transplant recipients, flucona­
zole was effective In preventing candidiasis but offered no prophylaxis against infections 
due to Aspergillus spp. and other molds, initial trials on the use of sprays and aerosols 
of amphotericin B and on infusions of low doses of this drug appeared beneficial, but 
the number of patients included was too small to allow any definite conclusion. Itracon­
azole offers promise, but it can only be given orally; adequate, reliable absorption is not 
yet guaranteed. While the lack of data justifies a wait-and-see approach in patients at 
low or moderate risk of developing a fungal infection, it seems reasonable to adminis­
ter prophylaxis to high-risk patients, even though there is presently no single agent suit­
able for all prophylactic purposes.
During the past decade, clinicians, investigators, 
and the pharmaceutical industry have focused 
more attention on fungal infections, which consti­
tute a major cause of morbidity and mortality in 
patients who receive bone marrow-ablative ther­
apy for malignant disease (1). Despite increased 
awareness and attempts to improve detection, 
the majority of fungal infections are diagnosed at 
autopsy (2). In up to 30% of cases of invasive fun­
gal infections found postmortem, patients had 
not received any antifungal therapy. This finding 
indicates that the diagnostic tools for detecting dis­
seminated fungal infection are insufficient. The in­
cidence of documented invasive fungal infection 
is approximately 7% of all febrile episodes in neu­
tropenic patients, but this incidence may be high­
er in some centers (Figure 1).
On the other hand, the increasing incidence of in­
vasive fungal infections is clearly associated with
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more effective antitumor strategies that induce 
greater mucosal damage and prolong neutropenia, 
as indicated by the increased incidence of fungal 
infections in bone marrow transplant recipients 
compared with patients receiving conventional cy- 
toreductive chemotherapy (Figure 1). The avail­
ability of powerful broad-spectrum antibacterial 
agents is another factor that undoubtedly plays a 
crucial role; the use of these agents has virtually 
eliminated early death due to gram-negative ba- 
cillary sepsis, thereby putting the patient at risk for 
other, subsequent infectious complications. The in­
cidence of invasive fungal infection may be in­
creased by extended antibacterial coverage 
(R. Feld et al, 32nd ICAAC, 1990, Abstract no. 
1695), possibly because the endogenous resident 
flora is suppressed, which seems to render the pa­
tient susceptible to ensuing fungal infection.
The extensive autopsy survey by Bodey et al. (2) 
revealed the presence of Candida spp. in 6 6% of 
cases and Aspergillus spp. in 30%, suggesting 
that many patients die either with or from a fun­
gal infection. Indeed, Candida spp. and Aspergil-
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Figure 1: Incidence of disseminated fungal infections in he 
matological malignancies versus bone marrow transplants 
tion in various centers that use no prophylaxis or oral poly­
enes only. Each bar represents the incidence of proven fun­
gal infection in a single center.
lus spp. now rank among the ten most prominent 
pathogens in patients undergoing treatment for 
hematological malignancies. Other fungi, such as 
Cryptococcus neoformans, Mucor spp., Fusarium 
spp., Alterneria spp.5 Trichosporon spp., and 
Geotrichum canclidum are seldom encountered. 
Candida albicans prevails among Candida spp., but 
Candida tropicalis, Candida glabrata, Candida 
parapsilosis, Candida pseudotropicalis and 
Candida krusei are increasingly isolated, even in 
centers where antifungal agents are used with cau­
tion. Some of these species present problems due 
to their intrinsic or acquired resistance to antifun»
I
gal agents, such as Candida krusei. Others have a 
clear propensity to cause invasive disease, such as 
Candida tropicalis, or to preferentially colonize 
central venous catheters, such as Candida parapsil­
osis. It is assumed that invasive candidiasis is pre­
ceded by colonization (3), which may be identified 
by surveillance cultures of the mucosal surfaces. 
However, colonization does not necessarily imply 
that a systemic infection will ensue. In marked con­
trast, aspergillosis is invariably acquired by inha­
lation of airborne Aspergillus spores. Infection 
may have been acquired before the patient be­
came neutropenic, but exogenous contamination 
during neutropenia is more likely. Air ventilation 
systems, construction sites, medication cartons, 
wet and dried flowers, pigeon droppings, pepper, 
and tea all have been implicated in outbreaks of 
Aspergillus infections in neutropenic patients.
General Issues and Rationale for Preventive 
Measures
Even with the most modern and sophisticated di-
deep-seated fungal infection at an early stage. As 
a result, by the time clinicians are confronted with 
infection it is well advanced and disseminated, and 
therefore difficult to cure. The mortality of cultu­
rally and/or histologically proven invasive fungal 
infections may exceed 90%, particularly when 
compounded by persistent neutropenia and under­
lying disease (4). Considering the limited efficacy 
of parenteral antifungal therapy and its high tox­
icity, many centers have made considerable efforts 
to prevent these infections.
However, before antifungal agents are used 
prophylactically, it is important to consider gener­
al measures to reduce the possibility of acquiring 
disseminated mycosis, Hand washing by visitors, 
nurses, doctors, and other personnel is of para­
mount importance; its neglect undermines all 
other, more sophisticated means of achieving op­
timal hygiene. Apart from hygiene, environ­
ments exposed to a high concentration of spores 
should be protected by HEPA-filtration, and 
well-known sources of fungi must be eliminated; 
this method is probably the most efficient way to 
reduce the number of nosocomial pulmonary as­
pergillosis cases in immunocompromised pa­
tients in centers with a high incidence of mold 
infections.
Other measures should also be considered. For in­
stance, hemorrhagic lesions might facilitate access 
and growth of fungi; therefore, thrombocyte 
transfusions may protect profoundly thrombocy­
topenic patients from fungal infection. Whenever 
feasible, surgical excision of aspergillomas should 
be considered.
Reducing the duration of neutropenia to minimize 
the risk of developing an infection has become an 
attractive option, but the use of hematopoietic 
growth factors to prevent fungal infections re­
quires further study. The availability of these 
growth factors might encourage clinicians to em­
ploy even more intensive cytoreductive chemo­
therapy that will cause more mucosal damage, 
thereby enhancing the potential for invasion by 
molds and yeasts. The intact mucosal barrier con­
stitutes a reliable defense mechanisms against in­
fection by these organisms, as demonstrated by the 
beneficial effects of antiviral agents that curtail 
mucosal damage resulting from herpes simplex in­
fection. (R. Feld et al., 32nd ICAAC, 1992, Ab­
stract no. 1695)
Unnecessary use of antibacterial agents and cor­
ticosteroids should be avoided, since both classes
agnostic tools, it is rarely possible to identify of drugs enhance the likelihood of a subsequent
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invasive fungal infection. Gastric antacids should 
be prescribed according to strict guidelines, be­
cause a low pH protects against colonization of the 
small and large intestine by Candida spp.
Assessment of the Prophylactic Use of Anti- 
fungal Drugs
Although there is little evidence to support this ap­
proach, antifungal drugs are often used during ag­
gressive treatment of malignant disease. Earlier 
studies on the prophylactic use of the polyenes 
(nystatin and amphotericin B) and the imida­
zoles (miconazole, ketoconazole, clotrimazole) 
are outdated. Their findings are no longer appli­
cable because the cytoreductive chemotherapy 
regimens for hematologic malignancies and solid 
tumors have changed substantially during the 
past decade. Although these drugs were somewhat 
effective in preventing superficial infections 
caused by Candida albicans, they were less effec­
tive in preventing disseminated mycoses (5).
It is doubtful that oral nystatin would have any 
beneficial effect, and there is scarce evidence that 
oral amphotericin B, considered the gold standard 
by many clinicians, is any more effective. This 
makes the question of whether sucking troches, 
pastilles, or lozenges is preferred over swallowing 
a suspension or tablets a trivial one. Further­
more, patient compliance with oral antifungal 
therapy with these agents is extremely variable, 
which inevitably nullifies any putative beneficial 
effects. Therapy with miconazole is similarly asso­
ciated with problems, since tolerance of the oral 
preparations is generally low, especially when the 
patient is suffering from oral mucositis. It was 
thought that ketoconazole would be well tolerat­
ed and more effective because it was absorbable; 
however, allergic reactions and liver function dis­
turbances have occurred with its use. Furthermore, 
clinical use of this drug has been associated with 
the selection of, and infection by, resistant 
Candida spp. as well as an increase in the rate of 
bacteremia (6). It must be emphasized that virtu­
ally all of the older studies as well as numerous re­
cent ones regarding prophylaxis against fungal in­
fections comprised a small number of mycologi- 
cally or histologically proven cases of mycosis, 
which makes the assessment of efficacy suspect be­
cause of the large type II error.
Many studies are conducted such that the results 
may not be generally applicable to clinical medi­
cine. Thus, the first step in assessing any given pub-
Table 1: Key items in the assessment of antifungal prophy­
laxis studies.
1. Were historical controls used? 
a. Were controls case-matched?
2. Was the study randomized?
a. Are statistics reliable?
b. Was the study conducted blindly?
3. What were the nature and stage of the underlying dis­
ease?
4. What was the duration of neutropenia?
5. How was response defined?
a. Was the occurrence of a fungal infection reported?
i. If documented, was it determined whether such 
an infection was superficial or disseminated?
ii. Were probable infections reported?
iii. Was refractory fever the only type reported?
b. Was the number of deaths attributable to the fungal 
infection reported? Were rates of infection determi­
nated at autopsy reported?
c. Was perceived need for empiric systemic antifungal 
agents investigated?
d. Was overall survival reported?
6. Was the influence of antifungal prophylaxis on colo­
nization assessed?
7. Were serum levels monitored (if relevant)?
8. Were adverse events and other quality'Of-life aspects 
mentioned?
a. Was patient compliance monitored?
b. Were interactions with other essential/unavoidable 
drugs determined?
9. Was a cost-benefit analysis performed?
lication is to check a number of key items (Table 
1) to ensure that the study population, the type of 
underlying diseases, and the degree and duration 
of neutropenia bear some resemblance to actual 
clinical situations. It is also important that patients 
are entered consecutively and allocated their reg­
imen at random, since historical controls are inad­
equate for evaluating the efficacy of an antifungal 
chemoprophylactic regimen.
The risk of infection varies considerably with 
time, due to changes in antitumor therapy regi­
mens as well as seasonal variations and building 
activity and renovation. Centers that experience 
a high incidence of serious invasive fungal infec­
tion are those most interested in developing new 
prophylactic strategies; therefore, results ob­
tained on this basis may look more impressive 
than they actually are, since any decrease in the 
incidence of mycosis is likely to be exaggerated, 
Moreover, the discipline involved in conducting a 
study often leads to better hygiene, better adher­
ence to diagnostic protocols, and more consistent 
application of criteria for infections. Compari­
sons with historical controls will also be mislead­
ing because it is impossible to correct for these bi-
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Figure 2: Results of various trials with fluconazole as pro- 
phylactic agent for fungal infections during neutropenia. Each 
bar represents a different trial; the daily dose of fluconazole 
is enclosed within each bar.
ases in nonrandomized studies, even when 
matched controls are used.
The two-part definition of the success or failure of 
prophylaxis deserves close attention: the direct im­
pact of prophylaxis on the number of proven in­
fections and the number of deaths attributable to 
fungal infection are crucial for the evaluation of 
antifungal agents, but the latter finding is seldom 
reported. In fact, autopsy results as regards fun­
gal infection are virtually never reported. In con­
trast, surrogate measures of outcome, such as the 
perceived need for systemic antifungal agents 
and overall survival, are frequently reported. 
Apart from efficacy, the safety, compliance, and 
costs associated with prophylaxis are all relevant 
points that may help the physician judge the po­
tential utility and limitations of a given strategy. 
It also must be underscored that many studies 
have a dual goal, namely to investigate infection 
caused by both molds and yeasts, yet each of these 
types of infection has a completely different epi­
demiology and a different portal of entry and thus 
requires a separate analysis. Finally, resorting to 
the literature is likely to be biased in favor of in­
tervention because reports of negative findings 
frequently are not published.
Antifungal Drugs in the Prevention of Invasive 
Mycosis
Yeast Infections. The aim of therapy with oral an­
tifungal agents is to reduce colonization of the gas­
trointestinal tract by yeasts, but there has been no
pending on the study setting. The newer triazoles 
are better tolerated than amphotericin B, nystatin, 
and ketoconazole, and they appear to be more ef­
ficacious than these older antifungal compounds. 
In a prospective, double-blind, placebo-con- 
trolled, multicenter study of patients undergoing 
bone marrow transplantation (7), prophylaxis 
with fluconazole at a dosage of 400 mg once dai­
ly was effective in preventing superficial and dis­
seminated candidiasis and in lowering overall 
mortality. These results were confirmed in a trial 
by Slavin et al. (8 ). The same results were found 
in a retrospective study performed at the Detroit 
Medical Center (9) in which a lower dosage 
(100-200 mg daily) was given. Therapy with 3 mg 
of fluconazole per kilogram body weight ap­
peared to be superior to oral nystatin or ampho­
tericin B in 502 children treated for malignancies 
(10). However, the superiority of fluconazole was 
less evident when this agent was administered 
prophylactically to adults during remission in­
duction therapy for acute leukemia (11-14). This 
finding might have been related to the various 
dosages used, which ranged from 50 to 400 mg 
daily, although there was no obvious relationship 
between the dosage and the ultimate results 
(Figure 2).
There is also a marked difference between Euro­
pean and North American views of the need for 
intravenous amphotericin B, which reflects differ­
ences in the attitude of physicians towards empir­
ic administration of this compound. Data from the 
study conducted by Goodman et al. (7), in which 
400 mg fluconazole was administered daily, are the 
most convincing, but the results from trials in 
which patients were treated at a lower dosage sug­
gest that half the dose may suffice in the majori­
ty of cases (10,14). Fluconazole was well tolerat­
ed at all dosage levels and was not associated with 
serious adverse effects apart from the tendency to 
select resistant Ctfnd/dflspp., particularly Candida 
krusei (15). Such selection of resistance may be a 
local phenomenon, because it was not mentioned 
as a problem in other prospective, randomized 
studies (10,12,13). Although fluconazole offers no 
protection against infections by Aspergillus spp., 
the overall prophylactic efficacy of this drug dur­
ing prolonged neutropenia appeared to compare 
to that of low-dose intravenous amphotericin B 
(16). These findings underscore the limitations 
inherent in assessing neutropenic patients en­
tered into a trial when the incidence of document-
consensus as to which regimen should be used. The ed invasive mold infections is low, since it will be 
impact of oral antifungal compounds on an inva- impossible to detect significant differences. Al- 
sive fungal infection remains controversial, de- though analysis of subgroups might provide a
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Figure 4 : Changing incidence of fungal infections in bone 
marrow transplant recipients in relation to the dosage of cor- 
ticosteroids for graft-versus-host disease (GVHD) and the use 
of antifungal prophylaxis (taken from reference 25).
better answer, in most clinical studies the low num­
ber of suitable patients with a defined diagnosis 
precludes a firm conclusion.
Mold infections. Even though the azoles and po­
lyenes show some promise in preventing super­
ficial and invasive candidiasis, they afford no pro­
tection against infection due to Aspergillus spp. 
and other molds, largely because mold infections 
are almost always acquired by inhalation of 
spores into airways that are inaccessible to non­
absorbable agents. Hence, other routes of admin­
istration have been explored.
In initial trials, amphotericin B sprays or inhalants 
(17-22) and low-dose infusions of amphotericin B 
(23-25) appeared to reduce the number of respir­
atory infections caused by Aspergillus spp. in pa­
tients undergoing bone marrow transplantation or 
remission induction therapy for hematologic ma­
lignancy. However, few patients were included in 
these trials, most of which were not conducted as 
prospective randomized studies. The rationale 
underlying these studies was delivery of a high 
concentration of aerosolized amphotericin B di­
rectly to the bronchi and bronchioli, which are 
considered the portal of entry in airborne infec­
tion. The incidence of pulmonary aspergillosis 
was lower in patients who received aerosolized 
amphotericin B than in historical controls, but 
overall mortality was not affected. Moreover, the 
incidence of disseminated aspergillosis was consid­
erably higher at participating centers before the 
trial than that reported in other surveys (Figure 3). 
However, a subsequent prospective, randomized 
study showed that the aerosol amphotericin B of­
fered no statistically significant advantage with re­
spect to the number of documented infections or 
overall survival (26). In fact, more cases of bacte­
remia were documented (26) in patients who in­
haled nebulized amphotericin B.Thus, until further 
investigations are undertaken, no firm conclu­
sions as to the efficacy of this strategy can be 
drawn.
Reduced dosages of 0.1 to 0.25 mg/kg/day intra­
venous amphotericin B or 0.5 mg/kg 3 days/week 
have been tested in a prophylactic setting, princi­
pally in bone marrow transplant recipients, in an 
attempt to reduce the drug’s toxicity while retain­
ing its excellent antifungal activity. However, 
most of these studies suffer from the same flaws 
as those that investigated nebulized amphotericin 
B and have come to similar conclusions (Figure 3), 
The combination of amphotericin B with cyclospo- 
rine may induce renal toxicity, which necessitates 
adjustment of the cyclosporine dosage and increas­
es the risk of graft-versus-host disease.
The questionable value of using historical controls 
for comparison was shown by O ’Donnell et al. 
(25), who reported an increased incidence of fun­
gal infections after high-dose corticosteroids 
were introduced to manage graft-versus-host dis­
ease in bone marrow transplant recipients (Figure 
4). This finding was particularly worrisome to the 
authors because the incidence of these infections 
had been remarkably low during the previous 
years; in fact, the local incidence was far below the 
average for similar patients and might have been 
underestimated as a result of lack of awareness, 
lack of diagnostic facilities, or use of less intensive 
chemotherapy for remission induction treatment. 
Once confronted with the apparent epidemic, the
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authors initiated a study that probably entailed im­
proved  clinical and microbiological surveillance, 
w h ich  increased the chances of detection. Imple­
m entation of the amphotericin B prophylaxis 
program  did decrease the incidence of fungal in­
fections, but not to the level observed before cor­
ticosteroids were introduced. After the initial de­
crease, however, the incidence actually rose again 
to  those levels reported by others.
A lthough  the liposomal formulations of ampho­
te ric in  B seem to offer a safe alternative to the de- 
oxycholate preparation, which is notorious for its 
toxicity, the clinical efficacy of these new com­
pounds  has not yet been proven (27). In addition, 
these drugs are too costly for use on a general 
basis.
In  contrast to fluconazole, itraconazole has dem­
onstrated clinical activity against Aspergillus spp.
(28 ,29 ) . Even before its registration, this oral com- Practical Guidelines for the Prophylactic Use of
The efficacy of itraconazole might also have been 
improved if more reliable absorption of the drug 
could have been achieved to ensure adequate se­
rum levels or if higher doses were used (30, 34). 
With the current formulation, serum concentra­
tions of itraconazole should be determined regu­
larly, especially in patients suffering cytotoxic 
therapy-induced mucosal damage or when ant­
acids are coadministered. At present, a new for­
mulation of itraconazole suspended in cyclodex- 
trin solution is being investigated and appears to 
be better absorbed (35). Other concerns about it­
raconazole have been identified: the induction of 
resistance to amphotericin B by previous exposure 
to itraconazole (36); the possible induction or in­
hibition of hepatic enzymes by itraconazole; the in­
teraction of itraconazole with cyclosporine; and 
the propensity of itraconazole to increase intracel­
lular levels of cytotoxic drugs such as vincristine 
and anthracyclines, which might enhance the tox­
ic effects of these agents.
When fluconazole or itraconazole is used prophy- 
lactically at adequate doses, neither is likely to be 
of benefit in treating proven or presumed invasive 
fungal infection, since it must be assumed that the 
offending pathogen is resistant to these drugs.This 
is not necessarily the case for oral amphotericin 
B, since the negligible amounts absorbed provide 
no useful systemic activity, although the outcome 
of patients who have been treated may still be less 
favorable (37).
p o u n d  produced encouraging results in prevent­
ing  serious fungal infections in small groups of 
neutropenic patients compared to historical con­
tro ls (30-32). However, in a prospective, double- 
b lin d , randomized study in leukemic patients
Antifungal Drugs
The efficacy of prophylactic use of antifungal 
drugs to prevent invasive fungal infections during 
episodes of prolonged and severe neutropenia is
w ho  were given oral amphotericin B, or itracon- not clear because reliable, prospective, randomized 
azole, 400 mg/day, neither reduced the incidence of studies are lacking, except for those that have in-
documented and presumed Aspergillus infections 
no r influenced the perceived need for intravenous 
amphotericin B (33), The serum levels of the 
drug  may have been inadequate in a substantial 
num ber of these patients, since many of them suf­
fered mucositis induced by aggressive chemo­
therapy. Although itraconazole did improve sup­
pression of Candida spp. in the gastrointestinal 
tract, these disappointing results might have been 
d iffe ren t had the drug concentration been moni­
to red  consistently during the trial and the dose of 
itraconazole adjusted accordingly.
vestigated fluconazole in this setting. A  survey of 
the literature showed that most strategies have 
produced results that differ little from those ob­
served in patients not given prophylactic agents 
(Figure 5). Even for fluconazole, by far the most 
widely tested drug, the data are equivocal; the pos­
sible exception is that daily dosing with 400 mg of 
fluconazole appears to offer some protection to 
bone marrow transplant recipients* All other op­
tions, including amphotericin B inhalation, re­
quire further exploration before definite recom­
mendations can be given.
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Although the lack of data justifies watchful wait­
ing, it seems reasonable to give patients at high risk 
of developing a life-threatening invasive fungal in­
fection the advantage of prophylactic treatment 
with an antifungal drug, preferably as part of a ran­
domized study. For example, if colonization by 
Candida spp., especially non-albicans strains, is en­
countered, prophylactic measures or early system­
ic antifungal therapy should be considered in a 
neutropenic patient (3, 38). Furthermore, pa­
tients with long-standing mucosal lesions who are 
being treated with broad-spectrum antibacterial 
agents for serious bacterial infections (39) and 
adult recipients of an allogeneic bone marrow 
transplant who are seropositive for cytomegalo­
virus and suffer from graft-versus-host disease (40) 
deserve the best antifungal prophylaxis available. 
Empiric parenteral amphotericin B may be a 
suitable alternative for neutropenic patients with 
persistent fever despite adequate broad-spec- 
trum antibacterial therapy (37,41) who have not 
yet developed a documented fungal infection.
Therapeutic doses of intravenous amphotericin B 
seem to be required to protect patients with pre­
vious aspergillosis against recrudescence during 
later cycles of intensive antileukemic therapy or 
bone marrow transplantation (42). Provided the 
serum levels are adequate, itraconazole could be 
administered as an alternative during the period 
between two consecutive neutropenic episodes 
(43-46).
Conclusion
Considering the limited data available, there is 
clearly a need for thorough, well-designed clinical 
research regarding the epidemiology, diagnosis, 
treatment, and prevention of invasive fungal infec­
tions in cancer patients. Although knowledge has 
increased, the information is patchy and not gen­
erally applicable. If we are to establish clinically 
useful guidelines for treating and preventing fun­
gal infections, cooperation between medical 
disciplines and medical centers is essential. 
The most crucial questions can be answered only 
by means of comprehensive clinical trials that 
require close cooperation between clinicians and 
microbiologists.
No single agent can be recommended to prevent 
all kinds of fungal infections under all circumstanc­
es. Most studies dealing with the prophylactic use 
of antifungal agents are difficult to evaluate be­
cause of methodological flaws, especially the low 
number of patients studied. Yet, measures for 
preventing fungal infections in neutropenic pa­
tients are clearly warranted because the use of 
more aggressive chemotherapy has led to a cor­
responding increase in the incidence of mycosis. 
In addition, timely diagnosis is seldom possible, 
and invasive fungal infections are associated with 
high mortality. Some general measures are obvi­
ous: practicing optimal hygiene, controlling the 
patient’s environment, and avoiding clearly haz­
ardous comedication. However, most recommen­
dations on the prophylactic use of antifungal 
agents are driven by concern about the outcome 
of a possible invasive fungal infection rather than 
on hard evidence derived from published 
observations.
Fluconazole prophylaxis seems proper for bone 
marrow transplant recipients, but even in this set­
ting its benefit is not clear because it has been as­
sociated with the selection of resistant Candida 
strains, and it offers no protection against mold in­
fection. The use of hematopoietic growth factors 
(discussed elsewhere in this issue) is based on thin 
evidence, although it is appropriate to offer anti­
fungal prophylaxis to patients at high risk of de­
veloping mycosis. These include patients experi­
encing severe mucosal damage who are also col­
onized with yeasts; those who are likely to 
experience prolonged neutropenia, particularly if 
it coincides with a cytomegalovirus infection 
and/or graft-versus-host disease; those who have 
undergone extensive abdominal surgery; and 
those receiving parenteral nutrition via a central 
venous catheter. The paucity of data, however, 
makes it impossible to achieve a consensus on the 
optimal prophylactic strategy. In fact, none of the 
presently available absorbable and nonabsorbable 
oral agents used for fungal chemoprophylaxis 
prevent infection or eradicate colonization 
consistently.
Fluconazole (150 to 400 mg daily) seems to be the 
best choice in circumstances that favor Candida or 
Cryptococcus infections, but it provides no protec­
tion against other frequent fungal infections in 
neutropenic cancer patients.
Amphotericin B administered by aerosol is a theo­
retically attractive option and is well-tolerated; 
however, promising results from clinical trials 
with historical controls have not been confirmed 
in a recent randomized trial. Hence, the value of
4
this approach remains unproven. The usefulness of 
prophylaxis with intravenous amphotericin B re­
quires further clinical investigation, but this drug
Current Topic: Fungal Infections Vol. 16,1997 39
should be given at the full dose to any patient with 
a history of a serious invasive fungal infection to 
safeguard against recrudescence during subse­
quent neutropenic episodes. Many clinicians ad­
minister 0.1 to 0.2 mg/kg/day amphotericin B in­
travenously (dubbed “Ampho-lite” by its critics) 
for prophylactic purposes in patients at risk to cir­
cumvent the toxicity associated with the standard 
dose. Again, the studies that support this ap­
proach have either used historical controls or 
have recruited few patients. Moreover, it is unclear 
whether low-dose amphotericin B would eradicate 
infections that usually respond to much higher 
doses.
The erratic absorption of itraconazole discourag­
es clinicians from using it for patients who are re­
ceiving antacids or who suffer from mucositis; its 
potential for interfering with the metabolism of 
other drugs and causing liver function distur­
bances deters them further. Yet, the drug still 
holds some promise for the future once a more re­
liable formulation becomes available for clinical 
use. Provided that adequate serum levels can be 
ensured, itraconazole might be used to bridge the 
period between consecutive neutropenic epi­
sodes in patients who have acquired an invasive 
fungal infection.
Until more convincing data become available, ev­
ery center must devise its own method for treat­
ing life-threatening invasive fungal infections in 
high-risk patients, based on local circumstances 
and prevailing pathogens. Until the value of the 
presently available chemoprophylaxis has been 
established, a wait-and-see strategy should be 
adopted for patients with a low or moderate risk 
of developing infection. In those at high risk, ear­
ly initiation of intravenous treatment with ampho­
tericin B at a therapeutic dose is favored when fun­
gal infection is suspected. A  major goal of the In­
vasive Fungal Infections Cooperative Group of 
the European Organisation for Research and 
Treatment of Cancer (EORTC) is to define more 
effective means of preventing fungal infection 
through investigation and subsequent validation.
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